<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00790283</url>
  </required_header>
  <id_info>
    <org_study_id>IBS/04-2007</org_study_id>
    <secondary_id>2008-A00111-54</secondary_id>
    <nct_id>NCT00790283</nct_id>
  </id_info>
  <brief_title>Assessment of the Numen Stent With Evaluation in a Randomized Study</brief_title>
  <acronym>ANSWERS</acronym>
  <official_title>Assessment of the Numen Stent With Evaluation in a Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Biomedical Systems S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>International Biomedical Systems S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to Evaluate the Short-Term and Mid-Term Safety and Efficacy of
      the NUMEN Cobalt-Chromium coronary stent for the treatment of de novo lesions in native
      coronary arteries and compare it to the VISION/MINIVISION coronary stent
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The success of bare metal coronary stenting is limited by the restenosis phenomenon, with
      rates depending on patient vascular morphology and lesion-related factors, the indication for
      and technique of stent deployment, and others. Drug-eluting stents (DES) improve the
      treatment of many coronary artery lesions by significantly reducing in-stent restenosis.
      However, there have numerous limitations resulting from the need for long-term dual
      antiplatelet therapy, the consequent bleeding risk (old patients, surgery, colon or gastric
      cancer, trauma), the unknown side-effects of long-term antiplatelet therapy, the cost
      associated with a long-term thienopyridine regimen, the body's reaction to the stent polymer,
      and the 0.2% per year increase in late stent thrombosis in comparison with bare metal stents
      (BMS).

      For these reasons, continuous research is devoted to improve the effectiveness of bare metal
      stents. The ideal stent should be non-thrombogenic, with a low rate of restenosis and late
      thrombotic events. The NUMEN stent has been designed to meet these criteria, using an
      extremely low stent strut thickness.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2008</start_date>
  <completion_date type="Anticipated">September 2009</completion_date>
  <primary_completion_date type="Anticipated">September 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative incidence of Major Adverse Cardiac Events (MACE), Cerebrovascular Events CVE) and Major Bleedings (according to TIMI classification)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Any death, cardiac death, stent related fatal / non fatal MI, TVR</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any death, cardiac death, stent related fatal / non fatal MI, TVR</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death, fatal/non fatal MI</measure>
    <time_frame>In hospital</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural success, TLR, TVR, ST</measure>
    <time_frame>In hospital</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Lesion</condition>
  <arm_group>
    <arm_group_label>Numen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vision/MiniVision</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PTCA with stent implantation</intervention_name>
    <description>Eligible patients will be randomly assigned to the implantation of one (or more) Numen or Vision/Mini Vision stent.
Each patient will undergo a 1-month follow-up and a clinical visit at 6 months from the procedure.</description>
    <arm_group_label>Numen</arm_group_label>
    <arm_group_label>Vision/MiniVision</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Clinical or instrumental documentation of stable/unstable myocardial ischemia or
             angina with a &gt;50% lesion on a major coronary vessel and/or side branch &gt; 2.0 mm

          -  Lesion length ≤ 20 mm

          -  Vessel requiring stent size with diameter ≥ 2.5 mm

        Exclusion Criteria:

          -  Age &lt; 18 years

          -  Life expectancy &lt; 6 months

          -  Chronic renal failure (serum creatinine &gt; 2 mg %)

          -  Ongoing acute myocardial infarction

          -  Left ventricular ejection fraction (LVEF) &lt;30%

          -  Cardiogenic shock

          -  Documented or suspected systemic and/or infectious disease

          -  Hypersensitivity to cobalt chromium or contrast media

          -  Anti-thrombotic drug intolerance

          -  Cardiac and/or extracardiac documented disease requiring surgical repair

          -  Patient is not an acceptable candidate for emergent coronary artery bypass surgery

          -  Primary or secondary pulmonary hypertension (by echo-doppler)

          -  Planned &gt; 2 stent implantation (except bail-out)

          -  Recent (&lt; 6 months) PCI or CABG

          -  Other type of stent implantation (also in case of bail-out)

          -  Visible endocoronary thrombosis

          -  Diffuse, severe coronary calcifications

          -  Use of debulking devices

          -  Extreme vessel tortuosity

          -  Unprotected left main stenosis (ULM)

          -  Bifurcation lesion

          -  In stent restenosis (ISR)

          -  Saphenous vein graft (SVG) and arterial by pass (internal mammary artery,IMA)

          -  Chronic total occlusion (CTO)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thierry Corcos, MD, FACC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Turin, Paris, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thierry Corcos, MD, FACC</last_name>
    <phone>+33-(0)1-40-088806</phone>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Cote de Nacre</name>
      <address>
        <city>Caen Cedex</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CMC De Parly II</name>
      <address>
        <city>Le Chesnay</city>
        <zip>78150</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinique Vert Coteau</name>
      <address>
        <city>Marseille Cedex 12</city>
        <zip>13375</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinique Valmente</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Privé Beauregard</name>
      <address>
        <city>Marseille</city>
        <zip>13012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Wittemberg</last_name>
      <phone>0033491121090</phone>
      <email>olwitt@aol.com</email>
    </contact>
    <investigator>
      <last_name>Olivier Wittemberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Turin</name>
      <address>
        <city>Paris</city>
        <zip>75006</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Thierry Corcos, MD, FACC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Alleray-Labrouste</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinique Saint Gatien</name>
      <address>
        <city>Tours Cedex</city>
        <zip>37042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2008</study_first_submitted>
  <study_first_submitted_qc>November 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2008</study_first_posted>
  <last_update_submitted>February 16, 2009</last_update_submitted>
  <last_update_submitted_qc>February 16, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2009</last_update_posted>
  <responsible_party>
    <name_title>Nader Shehata</name_title>
    <organization>International Biomedical Systems S.p.A.</organization>
  </responsible_party>
  <keyword>Treatment of de novo lesions in native coronary arteries</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

